Table 3 Renal complications by genotype in patients with tuberous sclerosis complex
| Â | TSC1 | TSC2 | P value |
|---|---|---|---|
(n = 21) | (n = 107) | TSC1 versus TSC2 | |
Renal AML | Â | Â | Â |
 AML | 20/21 | 104/107 | 0.52 |
 Bilateral AML | 19/21 | 103/107 | 0.26 |
 Diameter of the largest AML (cm) | 4.2 ± 1.7 | 5.6 ± 4.0 | 0.11 |
 Volume of largest AML (cm3) | 34 ± 39 | 159 ± 440 | 0.20 |
 AML stage |  |  |  |
  ≤ 4 | 18 | 66 | 0.044 |
  > 4 | 3 | 41 |  |
 Surgery/invasive procedure | 7/21 | 54/107 | 0.15 |
  Renal embolization | 6/21 | 31/107 | 0.97 |
  Nephrectomy/partial | 2/21 | 35/107 | 0.036 |
 mTOR Medication (Everolimus) | 4/21 | 68/107 | < 0.001 |
Renal cysts | Â | Â | 0.69 |
 Yes | 1 | 12 |  |
 No | 20 | 94 |  |
Renal cell carcinomas | Â | Â | 0.52 |
 Yes | 1 | 3 |  |
 No | 20 | 104 |  |
Ccr (ml/min) | 95 ± 20 | 90 ± 31 | 0.54 |
CKD stage | Â | Â | 0.073 |
 ≤ 2 | 20 | 82 |  |
 > 2 | 1 | 25 |  |
PKD | Â | Â | 0.99 |
 Yes | 0 | 3 |  |
 No | 21 | 104 |  |